Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

Table 1 Baseline demographic and disease characteristics of patients with AS stratified by prior anti-TNF therapy

	Patients with AS (N = 1,250)
			Prior TNF antagonist(s)			Reason for discontinuation of prior TNF antagonist^a
	No prior ETN/IFX	Prior ETN and/or IFX	IFX only	ETN only	IFX and ETN	Lack of response	Loss of response	Intolerance
Characteristic	(n = 924)	(n = 326)	(n = 162)	(n = 85)	(n = 79)	(n = 64)	(n = 115)	(n = 56)
Male (%)	71	72	78	59	72	75	66	68
Age (years; mean ± SD)	44 ± 12	44 ± 11	44 ± 10	44 ± 12	43 ± 10	45 ± 10	42 ± 10	44 ± 13
AS duration (years; mean ± SD)	11 ± 10	11 ± 9	12 ± 9	9 ± 9	11 ± 8	10 ± 9	11 ± 8	12 ± 10
HLA-B27 positive (%)	83	81	80	82	81	86	82	84
Peripheral arthritis (%)^b	22	25	26	27	19	23	24	34
Enthesitis (%)^c	55	55	52	57	60	50	56	64
Concomitant NSAIDs (%)	77	66	69	57	71	53	68	66
C-reactive protein (mg/dl)^d	1.3	1.2	1.4	1.1	1.1	1.4	1.6	0.8
	0.6, 2.6	0.5, 2.6	0.5, 3.0	0.4, 2.2	0.4, 2.6	0.7, 2.8	0.6, 2.7	0.3, 1.7

^aNo additional reason except for "other." ^bOne or more swollen joint count (0 to 44). ^cOne or more inflamed enthesis in Maastricht Ankylosing Spondylitis Enthesitis Score or fascia plantaris or both. ^dReference value, 0.4 mg/dl; values listed are median and quartile 1, quartile 3 because of skewed distribution. AS, ankylosing spondylitis; ETN, etanercept; IFX, infliximab; NSAIDs, nonsteroidal antiinflammatory drugs; TNF, tumor necrosis factor.

ISSN: 1478-6362